Oncology - Osteosarcoma Grants
The Oncology - Osteosarcoma Research Program Area remains a focus of the AKC Canine Health Foundation through support of research into the pathophysiology of osteosarcoma, as well as the genetic basis and identification of potential therapeutic drugs.
Active Grants:
| 03032-MOU | Early Detection of Canine Osteosarcoma |
| 03000 | Characterizing the Immunomodulatory Response of Histotripsy in Canine Osteosarcoma |
| 02991-A | Investigating Extracellular Crosstalk Between Canine Osteosarcoma and Macrophages |
| 03019 | Evaluation of a Targeted Anti αvβ3 Integrin Near-InfraRed (NIR-) Dye for Controlled Resection of Naturally Occurring Soft Tissue Sarcomas in Dogs |
| 03015 | The Immune and Molecular Landscape of Canine Osteosarcoma at the Single-Cell Level |
| 02999 | Evaluating Magnetic Resonance Imaging for Quantifying Histotripsy Ablation in Canine Osteosarcoma |
| 02768 | Defining the Functional Consequences and Therapeutic Vulnerability of Dystrophin Alterations in Canine Osteosarcoma |
| 02773 | Histotripsy for Treatment of Canine Appendicular Osteosarcoma |
| 02782 | Genetic Contribution to Early-onset Osteosarcoma |
| 01660 | Identifying the Genes That Confer Risk for Osteosarcoma |
Previously Awarded Grants:
| 02642-A | NF-kappaB Inactivation Enhances Apoptosis in Canine Osteosarcoma Cells |
| 02215 | A Cancer Vaccine for Canine Osteosarcoma |
| 1806 | A Novel Virus-Based Anti-Tumor Treatment for Canine Osteosarcoma |
| 01949-A | Targeting the Cell's Activation Machinery to Halt Tumor Metastasis in Canine Osteosarcoma |
| 01903-A | Defining the Anti-Tumor Activity of Monocytes in Osteosarcoma |
| 01726-A | Identifying Growth Factors That Promote the Spread of Osteosarcoma |
| 01672-A | Isolation and Characterization of Tumor Initiating Cells in Canine Osteosarcoma Cell Lines |
| 01704-A | Expression and distribution of Receptor Activator of Nuclear factor kB Ligand (RANK-L) and its receptor RANK in canine osteosarcoma |
| 01317 | Mutation Detection and Functional Analysis of Multiple Loci for Osteosarcoma |
| 01503-A | Rational Development of Targeted Therapy - Aurora Kinase Inhibition in Osteosarcoma |
| 01542-A | The Effects of Baicalein on Canine Osteosarcoma Cells |
| 00947B | Heritable and Sporadic Genetic Lesions in Canine Osteosarcoma |
| 982 | Evaluation of Efficacy of Fasaret in Dogs with Osteosarcoma |
| 976 | Investigating the Role of STAT3 Activation in Canine Osteosarcoma |
| 01192-A | Metabolism and Action of Gemcitabine in Canine Osteosarcoma Cell Lines |
| 778 | Role of Regulatory T Cells in Dogs with Osteosarcoma |
| 00757A | Hereditary Mutations in Genes Associated with Osteosarcoma in Large Dog Breeds |
| 01046-A | The Relevance of Ezrin in the Metastatic Progression of Canine Osteosarcoma |
| 00757B | Hereditary Mutations in Genes Associated with Osteosarcoma in Large Dog Breeds |
| 01178-A | Radiosensitization of Canine Osteosarcoma with Rapamycin |
| 00826-A | Percutaneous Cryoablation in Canine Osteosarcoma |
| 00373A | Mapping Genes Associated with Osteosarcoma in Large Dog Breeds |
| 00373B | Mapping Genes Associated with Osteosarcoma in Large Dog Breeds |
| 2629 | Clinical and Immunological Outcomes in Dogs with Osteosarcoma Treated with Intratumoral Interleukin-12 Microspheres |
The AKC Canine Health Foundation funds research in 23 different Research Program Areas for the health of all dogs. These program areas enable the Foundation to create depth in our research portfolio and help us to be responsive to the health concerns of our constituents.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.
